125 related articles for article (PubMed ID: 1976438)
1. Modulatory role for CCK-B antagonists in Parkinson's disease.
Boyce S; Rupniak NM; Tye S; Steventon MJ; Iversen SD
Clin Neuropharmacol; 1990 Aug; 13(4):339-47. PubMed ID: 1976438
[TBL] [Abstract][Full Text] [Related]
2. Subtype-selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathway.
Crawley JN
J Neurosci; 1992 Sep; 12(9):3380-91. PubMed ID: 1527584
[TBL] [Abstract][Full Text] [Related]
3. Differential involvement of CCK-A and CCK-B receptors in the regulation of locomotor activity in the mouse.
Vasar E; Harro J; Lang A; Pôld A; Soosaar A
Psychopharmacology (Berl); 1991; 105(3):393-9. PubMed ID: 1798834
[TBL] [Abstract][Full Text] [Related]
4. SCH 23390-induced hypophagia is blocked by the selective CCK-A receptor antagonist devazepide, but not by the CCK-B/gastrin receptor antagonist L-365,260.
Cooper SJ; Barber DJ
Brain Res Bull; 1990 Apr; 24(4):631-3. PubMed ID: 2141538
[TBL] [Abstract][Full Text] [Related]
5. Hypolocomotion induced by peripheral or central injection of CCK in the mouse is blocked by the CCKA receptor antagonist devazepide but not by the CCKB receptor antagonist L-365,260.
O'Neill MF; Dourish CT; Iversen SD
Eur J Pharmacol; 1991 Feb; 193(2):203-8. PubMed ID: 2050197
[TBL] [Abstract][Full Text] [Related]
6. Changes in motor activity and forebrain [propionyl-3H]propionylated-CCK-8 binding in mice after repeated administration of drugs affecting cholecystokinin receptors.
Vasar E; Stephenson JD; Meldrum BS
Eur J Pharmacol; 1991 Sep; 202(3):385-90. PubMed ID: 1748160
[TBL] [Abstract][Full Text] [Related]
7. Effects of CCK antagonists on CCK-induced suppression of locomotor activity in mice.
Hirosue Y; Inui A; Miura M; Nakajima M; Okita M; Himori N; Baba S; Kasuga M
Peptides; 1992; 13(1):155-7. PubMed ID: 1620653
[TBL] [Abstract][Full Text] [Related]
8. Different effects of CCK antagonists on gastric-acid response to CCK and pentagastrin.
Corwin RL; Smith GP
Peptides; 1993; 14(2):253-7. PubMed ID: 8483804
[TBL] [Abstract][Full Text] [Related]
9. Satiety induced by endogenous and exogenous cholecystokinin is mediated by CCK-A receptors in mice.
Weatherford SC; Chiruzzo FY; Laughton WB
Am J Physiol; 1992 Apr; 262(4 Pt 2):R574-8. PubMed ID: 1566921
[TBL] [Abstract][Full Text] [Related]
10. Evidence for potentiation by CCK antagonists of the effect of cholecystokinin octapeptide in the elevated plus-maze.
Vasar E; Lang A; Harro J; Bourin M; Bradwejn J
Neuropharmacology; 1994 Jun; 33(6):729-35. PubMed ID: 7936110
[TBL] [Abstract][Full Text] [Related]
11. The CCK-A receptor antagonist devazepide but not the CCK-B receptor antagonist L-365,260 reverses the effects of chronic clozapine and haloperidol on midbrain dopamine neurons.
Minabe Y; Ashby CR; Wang RY
Brain Res; 1991 May; 549(1):151-4. PubMed ID: 1893248
[TBL] [Abstract][Full Text] [Related]
12. Receptor mediation of the stimulus properties of cholecystokinin.
Melton PM; Riley AL
Pharmacol Biochem Behav; 1994 May; 48(1):275-9. PubMed ID: 8029299
[TBL] [Abstract][Full Text] [Related]
13. 'Anxiolytic' effect of CCK-antagonists on plus-maze behavior in mice.
Rataud J; Darche F; Piot O; Stutzmann JM; Böhme GA; Blanchard JC
Brain Res; 1991 May; 548(1-2):315-7. PubMed ID: 1868342
[TBL] [Abstract][Full Text] [Related]
14. Characterization of CCK receptors in a novel smooth muscle preparation from the guinea-pig stomach by use of the selective antagonists CI-988, L-365,260 and devazepide.
Boyle SJ; Tang KW; Woodruff GN; McKnight AT
Br J Pharmacol; 1993 Aug; 109(4):913-7. PubMed ID: 8401944
[TBL] [Abstract][Full Text] [Related]
15. CCK antagonists and CCK-monoamine interactions in the control of satiety.
Cooper SJ; Dourish CT; Clifton PG
Am J Clin Nutr; 1992 Jan; 55(1 Suppl):291S-295S. PubMed ID: 1728842
[TBL] [Abstract][Full Text] [Related]
16. Selectivity of cholecystokinin (CCK) receptor antagonists, MK-329 and L-365,260, for axonally-transported CCK binding sites on the rat vagus nerve.
Mercer JG; Lawrence CB
Neurosci Lett; 1992 Mar; 137(2):229-31. PubMed ID: 1374868
[TBL] [Abstract][Full Text] [Related]
17. Possible role of cholecystokinin-A receptors in regulation of thyrotropin (TSH) secretion in male rats.
Männistö PT; Peuranen E; Harro J; Vasar E
Neuropeptides; 1992 Dec; 23(4):251-8. PubMed ID: 1475033
[TBL] [Abstract][Full Text] [Related]
18. Cholecystokinin modulates both the development and the expression of behavioral sensitization to amphetamine in the rat.
Wunderlich GR; DeSousa NJ; Vaccarino FJ
Psychopharmacology (Berl); 2000 Aug; 151(2-3):283-90. PubMed ID: 10972475
[TBL] [Abstract][Full Text] [Related]
19. CCK-A receptors mediate the effect of cholecystokinin on vasopressin but not on cortisol in pigs.
Parrott RF; Forsling ML
Am J Physiol; 1992 Jun; 262(6 Pt 2):R1154-7. PubMed ID: 1621871
[TBL] [Abstract][Full Text] [Related]
20. Type-A CCK receptors mediate the inhibition of food intake and activity by CCK-8 in 9- to 12-day-old rat pups.
Smith GP; Tyrka A; Gibbs J
Pharmacol Biochem Behav; 1991 Jan; 38(1):207-10. PubMed ID: 2017446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
